Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma
- PMID: 18695901
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma
Abstract
This study aimed to investigate whether the expression of carbonic anhydrase IX (CAIX) is associated with the expression of vascular endothelial growth factor (VEGF) and whether the co-expression of the two correlates with survival outcome in clear cell renal cell carcinoma (ccRCC). The expression of CAIX and VEGF was evaluated immunohistochemically in 122 paraffin-embedded ccRCC specimens. The clinical significance of these markers in relation to disease-specific survival (DSS) was analyzed. Patients with a low expression of CAIX had a significantly worse prognoses than those with a high expression (p=0.0005). Inversely, patients with a high expression of VEGF had a significantly worse prognoses than the patients with a low expression (p=0.0030). Furthermore, CAIX expression significantly stratified the DSS of patients with high-stage (p=0.0001), high-grade (p=0.0392), low-grade (p=0.0273), metastasis (p=0.0034), no metastasis (p=0.0303) and ECOG-PS=0 (p=0.0003). VEGF expression significantly predicted the survival of patients with low-grade (p=0.0003), high-stage (p=0.0401) and ECOG-PS=0 (p=0.0063). A multivariate Cox regression analysis showed that tumor stage (p=0.0054), metastasis (p=0.0193), ECOG-PS (p=0.0065) and CAIX expression (p=0.0001) were independent prognostic factors of DSS. Since CAIX and VEGF expression correlated inversely (p=0.0032), the prognostic value of the co-expression of CAIX-VEGF was evaluated. Multivariate analysis revealed that the co-expression was an independent prognostic factor of DSS (p=0.0002). In addition, the co-expression was able to stratify DSS into three risk groups: high-risk, intermediate-risk and low-risk (p<0.0001). In patients with ccRCC, CAIX and VEGF expression correlated inversely. Independent expression of CAIX and a co-expression of CAIX-VEGF were found to be independent predictors of DSS. Furthermore, the co-expression data for CAIX-VEGF provide more accurate prognostic information than the individual data. This information may be useful for survival prediction and risk stratification of patients with ccRCC.
Similar articles
-
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.J Clin Oncol. 2007 Oct 20;25(30):4757-64. doi: 10.1200/JCO.2007.12.1087. J Clin Oncol. 2007. PMID: 17947723
-
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.BJU Int. 2013 Jun;111(7):1046-53. doi: 10.1111/bju.12075. Epub 2013 Apr 2. BJU Int. 2013. PMID: 23551810
-
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.Clin Cancer Res. 2003 Feb;9(2):802-11. Clin Cancer Res. 2003. PMID: 12576453
-
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.Eur Urol. 2010 Jul;58(1):75-83. doi: 10.1016/j.eururo.2010.03.015. Epub 2010 Mar 23. Eur Urol. 2010. PMID: 20359812 Review.
-
Biomarkers in renal cell carcinoma.Curr Opin Urol. 2009 Sep;19(5):441-6. doi: 10.1097/MOU.0b013e32832f0c68. Curr Opin Urol. 2009. PMID: 19584732 Review.
Cited by
-
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.Curr Oncol. 2009 May;16 Suppl 1(Suppl 1):S60-6. Curr Oncol. 2009. PMID: 19478895 Free PMC article.
-
Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.Int J Oncol. 2019 Aug;55(2):371-390. doi: 10.3892/ijo.2019.4830. Epub 2019 Jun 25. Int J Oncol. 2019. PMID: 31268155 Free PMC article.
-
HuR expression is a marker of poor prognosis in renal cell carcinoma.Tumour Biol. 2011 Jun;32(3):481-7. doi: 10.1007/s13277-010-0141-6. Epub 2010 Dec 16. Tumour Biol. 2011. PMID: 21161467
-
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Clin Exp Metastasis. 2014 Jan;31(1):111-34. doi: 10.1007/s10585-013-9612-7. Clin Exp Metastasis. 2014. PMID: 23959576 Review.
-
Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma.Oncol Lett. 2012 Feb;3(2):490-496. doi: 10.3892/ol.2011.511. Epub 2011 Dec 2. Oncol Lett. 2012. PMID: 22740938 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical